Most Traveled People Summit 2025: A Gathering of the World's Most Adventurous Travelers in Addis Ababa, Ethiopia in November 2025
8.5.2025 10:00:00 CEST | Business Wire | Press Release
The Most Traveled People (MTP) community is thrilled to announce the MTP Summit 2025, set to take place in the fascinating city of Addis Ababa, Ethiopia from 13 to 16 November 2025. This highly anticipated event, supported by the Ethiopian Ministry of Tourism, will bring together the world's most experienced travelers, offering a unique platform for networking, learning, and exploring. The event will take place in the Sheraton Addis, one of Africa’s most prestigious hotels, combining modern luxury with traditional Ethiopian influence.
MTP is the largest extreme travel community in the world, with over 40,000 members who aspire to explore every region in the world. The platform also serves as a system of record for collectors of the world's best countries, regions and World Heritage Sites, as well as restaurants, beaches, hotels, golf courses, and more. MTP connects like-minded adventurers, making travel planning easier and more enriching.
The MTP Summit 2025 promises an impressive lineup of activities and speakers:
- Masterclass Sessions: During the Summit, attendees will benefit from masterclass-level insights delivered by ten renowned speakers, covering topics from assessing risk around you to extreme travel.
- Networking Opportunities: Meet and connect with some of the world's most traveled individuals, sharing experiences and tips.
- Curated Cultural Experiences: Participate in exclusive experiences organized by MTP, exploring the rich culture and history of Ethiopia. MTP will be organizing side trips before, around and after the Summit for participants to get to know one another, network and explore the surrounding areas.
Featured speakers include the following inspirational adventurers, with more to be announced:
- Amos Nachoum: A world-renowned underwater photographer and founder of Big Animals Expeditions. Amos's award-winning work has been featured in National Geographic and BBC Wildlife Photographer of the Year, inspiring a deep connection with the ocean.
- Hayley Kennedy: The first known disabled woman to visit all 193 United Nations member states. Hayley will share stories from her journey around the world and insights on making travel more accessible.
- Johnny Ward: A travel entrepreneur and blogger who turned his passion for travel into a multimillion-dollar business. Johnny will discuss pushing boundaries in extreme travel and lifestyle design.
Charles Veley, Founder and Chairman of MTP, commented:
"We’re thrilled to be hosting this year’s MTP Summit in Ethiopia, a land of rich history with stunning landscapes and vibrant cultures. The event promises to be a platform for learning, connection, and inspiration for inquisitive travelers from around the globe.
“We are delighted to receive the support of the Ethiopian Ministry of Tourism and eagerly anticipate welcoming passionate travelers, sharing stories of exploration, and celebrating the incredible experiences that have shaped our journeys. Together, we will inspire one another to continue discovering the wonders of our world.”
For more information and to register, visit the MTP Summit 2025 Website: https://mtp.travel/mtp-summit-2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508700552/en/
Contacts
Justyna Janawa, Head of Operations
Phone: +48 603 675 638
Email: contact@mtp.travel
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom